Quantus

Dong Sung Bio Pharm.Co.,Ltd.

A002210 · KOSPI
₩1,846+2.56%
2026-08-03 close
Loading chart…
CloseMA20MA60MA120
AI Insight

Why these signals fired — only backtest-proven edge, told honestly

Why this signalSignal guide

Moving-average alignment
Yes · score 0.88
Explore this stock further
Review signal, financial and filing context in chat
Explore in chat →

Strong-buy signal — the real recordrecord · not a prediction

Not this one stock, but every strong-buy pick we actually published (Korea market). When this stock flashes the signal, it is treated by the same rule.(as of 2026-08-03)

Last 30 sessions
648 picks
Next-day win rate
49.2%
Avg next-day
-0.17%
vs market
+0.72%p

Beat the market on 62.1% of picks (each pick vs its own day’s market average).

Recent publish days (next-day win rate)
07-31 0%07-30 66.7%07-29 0%07-28 45%07-27 20%07-25 36.4%07-21 55.6%07-20 53.8%07-16 53.3%07-15 50%07-14 71.4%07-13 31.2%
This stock has not flashed this signal recently — the record above is the signal’s own, not this stock’s.

Entry is the latest close at publish time; next-day is the following close. “Market” is the equal-weighted average of every stock in the same market that day; delisted names are excluded from both. Fees, taxes and slippage are not included. An observed record over a short window, not a pre-registered backtest. Not investment advice.

Financial safety

Reference indicatorAs of 2024
Distress zoneFinancial-metric reference signal
Altman Z'' zoneZ'' -0.19
Distress
Grey
Safe
The marker shows the current Z'' value within the displayed zones.
Altman Z''
-0.19
Beneish M-Score
-2.12

No statistical flag

Sloan accrual
1.77%

부실·조작 위험을 나타내는 사실 지표입니다. 투자 조언이 아니며, 검증 전이라 참고용입니다.

Factual information, not investment advice.

Why has this company moved this way?

Auditable observations with the original numeric evidence.

매출 하락 → 마진 압박 → 현금 악화

Critical

매출이 -0.2% 감소하며 영업이익률이 -0.3%에서 -7.5%로 하락했다. 영업현금흐름도 동반 감소하여 수익-현금 순환이 약화되고 있다.

Evidence

매출 YoY -0.2% (2023→2024)영업이익률 -0.3%→-7.5%영업CF -4,293→-9,943

차입 증가 → 이자부담 → 수익성 악화

Critical

부채가 +28.7% 늘며 이자보상배율이 -0.1x에서 -1.8x로 하락했다. ROE도 -0.7%에서 -12.0%로 낮아져 차입 부담이 수익성을 누르고 있다.

Evidence

부채 YoY +28.7%이자보상배율 -0.1x→-1.8xROE -0.7%→-12.0%

Factual information, not investment advice.

Earnings quality · Piotroski F-Score

2/9Weak

Piotroski measures year-over-year financial improvement, not absolute quality.

Financial improvement score2/9

Profitability

  • Positive ROANot passed
  • Positive OCFNot passed
  • Improving ΔROANot passed
  • Accruals (OCF > net income)Not passed

Leverage & liquidity

  • Lower debtPass
  • Higher current ratioNot passed
  • No new sharesPass

Efficiency

  • Higher gross marginNot passed
  • Higher asset turnoverNot passed

Calculation note: F7(신주)은 equity/asset 유지로 근사

Already-stable companies may score lower when year-over-year improvement is limited.

Factual information, not investment advice.

Forensic signals

Anomaly and structural signals observed in the financial statements.

Revenue qualityDanger

매출 흑자인데 영업CF 적자 (OCF/매출 -11%). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Revenue qualityWarning

OCF/매출 3기 연속 하락. 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Margin trendWarning

영업이익률 악화 (-0.3% → -7.5%, -7.2%p). 통계적 정황 신호이며 회계부정 단정이 아닙니다.

Factual information, not investment advice.

Risk sensitivity — adverse assumptions

Metric changes under stated assumptions; not a forecast or investment advice.

Base metrics

Operating margin
-7.5%
Interest coverage
-1.8x
Return on equity (ROE)
-13.1%

Operating margin −5pp

Operating loss
Interest coverageBase -1.8x adverse case -3x
Return on equity (ROE)Base -13.1% adverse case -26.8%

Revenue −15%

Interest coverage risk
Interest coverageBase -1.8x adverse case -1.5x
Return on equity (ROE)Base -13.1% adverse case -17%

Interest rate +2pp

Interest coverage risk
Interest coverageBase -1.8x adverse case -1.2x
Return on equity (ROE)Base -13.1% adverse case -22.3%

Interest coverage limit

Already below the limit by 11.7pp

Interest coverage limit at an operating margin of 4.2%

Interest expense coverage threshold

Key suppliers · Annual report

Annual reportDART · 2026-05-06

Suppliers disclosed by the company in its 2026-05-06 annual report.

Purchase amount

KRW 100m
  1. 국전약품
    KRW 154.1B
  2. ZML
    KRW 81.2B
  3. 팜피아
    KRW 68.4B
  4. 하이플
    KRW 54B
  5. 기타
    KRW 20.4B

Financials at a glance

Dong Sung Bio Pharm.Co.,Ltd.'s latest results and balance sheet. The bars track the last three periods.

Who held it · filings

Filed record

A historical record from curated-guru 13F filings and DART 5%+ major-holding disclosures.

US 13F는 분기 공시이며 최대 45일 뒤 제출될 수 있습니다.

5%+ major-holding disclosures

  • 유암코제약산업제1호기업재무안정사모투자81.98%2026-04-15 · 증감 +9.34%p
  • 이양구21.26%2025-04-01 · 증감 0.00%p
  • 브랜드리팩터링14.41%2025-07-31 · 증감 0.00%p

Connections

AI-extracted related companies · for reference

Same theme
이노션헬스케어화장품
🔗 See in the full market map →

Recent filings

Dong Sung Bio Pharm.Co.,Ltd.'s latest filings on Korea's DART. Open a headline for a reference summary and the original.

Source: DART (Korea electronic disclosure)

Signal history (last ~2 years)

Every occurrence on this stock, with the return 20 trading days later. Small sample — a record, not a prediction.

Golden cross×1
26-07-31·
New MA alignment×1
26-07-31·

“·” = fewer than 20 trading days since the event. Cup-and-handle entries are days our board actually showed the badge (archive grows daily since 2026-05-12); others are recomputed from price data.

Like these rules? Run them automatically.

Quantus turns rules like these into backtests and automated trading — same team, free to start.

Quantus Signal · live data · not investment advice · Privacy Policy